RAVULIZUMAB is a new drug approved for treatment of?
RAVULIZUMAB : It is monoclonal antibody against C5 complement component. PNH is a rare acquired disorder that leads to hemolysis. Ravulizumab is a longest acting complement inhibitor that prevents hemolysis. Given intravenously every 8 weeks. Another monoclonal antibody against C5, eculizumab is given every 2 weeks. It carries a black box warning of risk of meningococcal infection / sepsis. Therefore patient should be vaccinated for meningococcal disease. VOXELOTOR is used for oral treatment of sickle cell anemia. GIVOSIRAN is used for Acute hepatic prophyria.
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
SICKLE CELL ANEMIA
ACUTE HEPATIC PROPHYRIA
MENINGOCOCCAL INFECTIONS
Hematology